

CURRICULUM VITAE

CURRICULUM VITAE



PERSONAL INFORMATION

Name Francesca Spinella

Address

Telefon

Fax

E-mail

Nationality Italian

Date of birth

CURRENT EMPLOYMENT STATUS

From -to 3-1-2014 today
Name and address of employer Eurofins GENOMA Group s.r.l. Via di Castel Giubileo,
11, 00138 Rome, Italy.

Occupation Molecular Genetics Laboratory
Via Di Castel Giubileo, 11, Roma
International Business Manager
R&D Director

EDUCATION

1990-1995
Degree in Biological Science
University of Catania, Italy,
Faculty of Biological Science

1995-1999
PhD in Neurobiology

University of Catania, Italy

ADDITIONAL INFORMATION

Participation in national and international conferences as a speaker:

- European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting virtual meeting. 26-1 July 2021.
- European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting Virtual meeting: 5-8 July 2020
- European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting. Vienna 2019, 23-26 June 2019. Invited speaker "Impact of chromosomal mosaicism in IVF outcomes".
- Lesson for the teaching of human genetics (master's degree in genetics and molecular biology), at the Sapienza University of Rome. Title: Clinical applications of Next generation sequencing " Rome, May 14th 2019
- European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting. "New evidence on mosaic developmental potential: two hundred mosaic embryos transferred prospectively in a single clinic " Vienna 2019, 23-26 June 2019. Selected oral presentation
- Seminar in Applied Human Genetics, Sapienza University Rome part of the PhD program in Genetics and Molecular Biology. Title: "Clinical application of next generation sequencing" Rome, 18- January 2018.
- Preimplantation Genetic Diagnosis International Society (PGDIS), Ginevra 15-18 April 2018
- 4° European Fertility Meeting: Strategies to improve IVF success rate Congresso Nazionale SIRU. Rome, 1-2 December, 2018
- SIRU Annual Congress "Costruiamo la medicina e la biologia della riproduzione umanizzata". Rome, 14-16 December 2017
- Preimplantation Genetic Diagnosis International Society (PGDIS), Valencia 26-29 March 2017
- Preimplantation Genetic Diagnosis International Society (PGDIS), Bologna 8-11 May 2016
- Preimplantation Genetic Diagnosis International Society (PGDIS), Chicago 9-13 May 2015
- American Society Reproductive Medicine (ASRM) Annual Meeting-Honolulu, Hawaii-18-22 October 2014
- 13th International Conference on Endothelin, Tokyo, Japan, 11 September 2013 (Keynote lecture)
- 12th International Conference on Endothelin, Cambridge, 11 September 2011
- Centro Ricerca Sperimentale; Istituto Regina Elena, Roma 3-Marzo 2009
- Seminario presso l'Istituto Dermatologico Italiano, Roma 10 Febbraio 2009
- Workshop SIICA, Angiogenesi: basi molecolari ed implicazioni terapeutiche II, Siena 21-23 Maggio 2008

- Congresso Nazionale della Società Italiana di Cancerologia, Bergamo, 26-Novembre, 2007
- Centro Ricerca Sperimentale; Istituto Regina Elena Roma 14 Novembre 2007
- 10th International Conference on Endothelin, Bergamo, 25 Settembre 2007
- Pezcoller Foundation Symposium. Pordenone, 10 Settembre 2007
- 9th International Conference on Endothelin. Park City, Utah, 11 Settembre 2005
- Meeting “Meccanismi di trasduzione del segnale in adesione e differenziamento cellulare”, Roma 19 Marzo 2004

Membership

Chair of the PGT Consortium ESHRE

Patent “Metodo per la diagnosi in vitro di un cancro di testa e collo e relativo kit”. The national patent was filed in 2019 and the international one in 2021 (excluding the USA). Domanda di Brevetto per Invenzione No. 102020000017896 depositata in Italia il 23/07/2020

Prize and Grant

- Pezcoller Fundation, Pezcoller Fundation Symposium. Pordenone, September 10-15, 2007
- The Fourth International Conference on "Tumor microenvironment: progression, therapy and prevention" Florence, March 6-10, 2007
- Travel Award Ninth International Conference on Endothelin. Park City, Utah , September 11-14 , 2005
- **Funding for research projects**
- “Progetto Giovani Ricercatori 2000-MURST “
- Principal Investigator “My First Grant” finanziato dall’AIRC



2010/2012. AIRC

- “POR FESR Lazio 2014-2020 CONTRIBUTI PER IL SOSTEGNO DEI PROCESSI DI INTERNAZIONALIZZAZIONE DELLE PMI DEL LAZIO Lazio Innova “
- “POR FESR 2014-2020”



REGIONE
LAZIO



Publications

- 1) Ciccarelli R., Suredda F., Casabona G., Di Iorio P., Caruso A., Spinella F., Condorelli D.F., Nicoletti F, and Caciagli F. *Opposite influence of metabotropic glutamate receptor subtypes mGlu3 and 5 on astrocyte proliferation in culture.* **Glia** (1997) 4:390-398. **I.F. 4.3**
- 2) Condorelli D.F., Dell'Albani P., Corsaro M., Giuffrida R., Caruso A., Trovato Salinaro A., Spinella F., Nicoletti F., Albanese V., and Giuffrida Stella A. M. *Metabotropic glutamate receptor expression in cultured rat astrocytes and human gliomas.* **Neurochem Res** (1997) 9:1127-1133. **I.F. 2.2**
- 3) Condorelli D.F., Parenti R., Spinella F., Trovato Salinaro A., Belluardo N., Cardile V. and Cicirata F. *Cloning of a new gap junction gene (Cx36) highly expressed in mammalian brain neurons.* **Eur J Neurosci** (1998) 10: 1202-1208. **I.F. 4**
- 4) Condorelli D.F., Trovato Salinaro A., Spinella F., Valvo S., Saponara R., and Giuffrida S. *Rapid touchdown PCR assay for the molecular diagnosis of spinocerebellar ataxia type 2.* **Int J Clin Lab Res** (1998) 28: 174-178. **I.F. 1.2**
- 5) Huang C.J., Spinella F., Nazarian R., Lee M.M., Dopp J.M. and de Vellis J. *Expression of Green Fluorescent Protein in Oligodendrocytes in a Time- and Level-Controllable Fashion with a Tetracycline-Regulated System.* **Mol Med** (1999) 2:129-137. **I.F.3.35**
- 6) Giuffrida S., Lanza S., Restivo D.A., Saponara R., Valvo S.C., Le Pira F., Salinaro A.T., Spinella F., Nicoletti A., and Condorelli D.F. *Clinical and molecular analysis of 11 Sicilian SCA2 families: influence of gender on age at onset.* **Eur J Neurol** (1999) 3: 301-307. **I.F. 4**
- 7) Cicirata F., Parenti R., Spinella F., Giglio S., Tuorto F., Zuffardi O., and Gulisano M. *Genomic organization and chromosomal localization of the mouse Connexin36 (mCx36) gene.* **Gene** (2000) 251:123-130 . **I.F. 2.7**
- 8) Gulisano M., Parenti R., Spinella F. and Cicirata F. *Cx36 is dynamically expressed during early development of mouse brain and nervous system.* **NeuroReport** (2000) 11: 3823-3828. **I.F. 2**
- 9) Rosanò L., Varmi M., Di Castro V., Spinella F., Natali P.G. and Bagnato A.. *Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.* **Cancer Res** (2001) 61: 8340-8346. **I.F. 8.6**
- 10) Del Bufalo D., Di Castro V., Biroccio A., Varmi M., Salani D., Rosanò L., Trisciuglio D., Spinella F. and Bagnato A. *Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for AKT activation.* **Mol Pharmacol** (2002) 61: 524-532. **I.F. 4.6**
- 11) Spinella F., Rosanò L, Di Castro V, Natali PG, Bagnato A. *Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1 alpha in ovarian carcinoma cells.* **J Biol Chem** (2002) 277: 27850-27855. **I.F. 5.85**
- 12) Rosanò L., Salani D., Di Castro V., Spinella F., Natali PG., and Bagnato A. *Endothelin-1 promotes proteolytic activity of ovarian carcinoma.* **Clin Sci** (2002) 102: 306S-309S. **I.F. 2.6**
- 13) Salani D., Rosanò L., Di Castro V., Spinella F., Venuti A., Padley R.J., Nicotra M.R., Natali PG., and Bagnato A. *ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian growth in vitro.* **Clin Sci** (2002) 102: 318S-21S. **I.F. 2.6**
- 14) Del Bufalo D., Di Castro V., Biroccio A., Salani D., Rosanò D., Spinella F., and Bagnato A. *Endothelin-1 acts as a survival factor in ovarian carcinoma cells.* **Clin Sci** (2002) 102: 302S-305S. **I.F. 2.6**
- 15) Dopp JM., Sarafian TA., Spinella F., Kahn MA., Shau H., de Vellis J. *Expression of the p75 TNF receptor is linked to TNF-induced NFkappaB translocation and oxyradical neutralization in glial cells.* **Neurochem Res** (2002) 27:1535-1542. **I.F. 2.2**
- 16) Bagnato A., Spinella F. *Emerging role of endothelin-1 in tumor angiogenesis.* **Trends Endocr Metab** (2003) 1: 44-50. **I.F. 7.22**
- 17) Rosanò L., Spinella F., Salani D., Di Castro V., Venuti A., Nicotra M.R., Natali P.G., Bagnato A. *Therapeutic*

- targeting of the endothelin A receptor in human ovarian carcinoma. **Cancer Res** (2003) 63: 2447-2453. **I.F. 8.6**
- 18) Rosanò L., Spinella F., Di Castro V., Ricci R., Nicotra M.R., Albini A., Natali P.G., Bagnato A. *Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo.* **Am J Pathol** (2003) 63:2447-2453. **I.F. 5.79**
 - 19) Spinella F., Rosanò L., Di Castro V., Nicotra MR., Natali P.G., Bagnato A. *Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells.* **J Biol Chem** (2003) 278:41294-41301. **I.F. 5.85**
 - 20) Bagnato A., Rosanò L., Spinella F., Di Castro V., Tecce R., Natali P.G. *Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression.* **Cancer Res** (2004) 64: 1436-1443. **I.F. 8.6**
 - 21) Spinella F., Rosanò L., Di Castro V., Nicotra M.R., Natali PG., Bagnato A. *Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.* **Clin Cancer Res** (2004) 10: 4670-4679. **I.F. 7.8**
 - 22) Spinella F., Rosanò L., Di Castro V., Natali P.G., Bagnato A. *Endothelin-1-induced prostaglandin E2-EP2,EP4-signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion.* **J Biol Chem** (2004) 279: 46700-46705. **I.F. 5.85**
 - 23) Rosanò L., Spinella F., Genovesi G., Di Castro V., Natali PG. and Bagnato A, *Endothelin B receptor blockade inhibits molecular effectors of melanoma cell progression.* **J Cardiovasc Pharmacol** (2004) 44, S136-S139. **I.F. 1.13**
 - 24) Rosanò L., Spinella F., Di Castro V., Natali P.G., Bagnato A. *Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma: efficacy of the cytotoxic agents is markedly enhanced by coadministration with atrasentan.* **J Cardiovasc Pharmacol** (2004) 44, S132-S135. **I.F. 1.13**
 - 25) Spinella F., Rosanò L., Elia G., Di Castro V., Natali P.G., Bagnato A. *Endothelin-1 stimulates cyclooxygenase-2 expression in human ovarian carcinoma cells through multiple signaling pathways: evidence for involvement of the epidermal growth factor receptor.* **J Cardiovasc Pharmacol** (2004) 44, S140-S143. **I.F. 1.13**
 - 26) Bagnato A., Spinella F., Rosanò L. *Emerging role of the endothelin axis in ovarian tumor progression.* **Endocr Relat Cancer** (2005) 12:761-72. **I.F. 4.9**
 - 27) Rosanò L., Spinella F., Di Castro V., Nicotra M.R., Dedhar S., de Herreros AG., Natali PG., Bagnato A. *Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.* **Cancer Res** (2005) 65:11649-57. **I.F. 8.6**
 - 28) Rosanò L., Spinella F., Di Castro V., Dedhar S., Nicotra M.R., Natali PG., Bagnato A. *Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.* **Mol Cancer Ther** (2006) 5:833-42. **I.F. 5.1**
 - 29) Rosanò L., Di Castro V., Spinella F., Decandia S., Natali PG., Bagnato A. *ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.* **Exp Biol Med** (2006) 231:1132-5. **I.F. 2.8**
 - 30) Rosanò L., Spinella F., Di Castro V., Decandia S., Nicotra M.R., Natali PG., Bagnato A. *Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.* **Exp Biol Med** (2006)231:1128-31. **I.F. 2.8**
 - 31) Spinella F., Rosanò L., Decandia S., Di Castro V., Albini A., Elia G., Natali PG., Bagnato A. *Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target.* **Exp Biol Med** (2006) 231:1123-7. **I.F. 2.8**
 - 32) Spinella F., Rosanò L., Decandia S., Di Castro V., Albini A., Nicotra M.R., Natali PG., Bagnato A. *Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.* **Mol Cancer Ther** (2006) 5:1483-92. **I.F. 5.1**
 - 33) Spinella F., Rosanò L., Di Castro V., Decandia S., Nicotra M.R., Natali PG., Bagnato A. *Endothelin-1 and -3 promote invasive behaviour via hypoxia-inducible factor-1a in human melanoma cells.* **Cancer Res.** (2007) 67 : 1725-1734. **I.F. 8.6**
 - 34) Rosanò L., Di Castro V., Spinella F., Nicotra M.R., Natali PG. and Bagnato A. *ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.* **Mol Cancer Ther** (2007) 6: 2003-11. **I.F. 5.1**
 - 35) Rosanò L., Di Castro V., Spinella F., Tortora G., Nicotra M.R., Natali PG. and Bagnato A. *Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.* **Cancer Res** (2007) 67:6351-9 **I.F. 8.6**
 - 36) Bagnato A., Spinella F., Rosanò L. *The endothelin axis in cancer: the promise and the challenges of molecularly*

targeted therapy. **Can J Physiol Pharmacol.** (2008) 8:473-84 **I.F. 1.8**

- 37) Rosanò L., Cianfrocca R., Masi S., Spinella F., Di Castro V., Biroccio A., Salvati E., Nicotra M.R., Natali PG., and Bagnato A. *β -arrestin links endothelin A receptor to β -catenin signaling to induce ovarian cancer cell invasion and metastasis.* **PNAS** (2009) 106:2806-11 **I.F. 9.598**
- 38) Spinella F., Emirena G., Di Castro V., Rosanò L., Nicotra M.R., Caruso A., Natali PG., and Bagnato A. *Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.* **Cancer Res.** (2009) 69: 2669-76 **I.F.8.6**
- 39) Rosanò L, Spinella F., Bagnato A. *The importance of endothelin axis in initiation, progression and therapy of ovarian cancer.* **Am J Physiol Regul Integr Comp Physiol.** (2010). **I.F.3.3**
- 40) Spinella F., Rosanò L, Del Duca M, Di Castro V, Nicotra MR, Natali PG, Bagnato A. *Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1 α in melanoma cells.* **PLoS One.** (2010) 5:e11241 **I.F.4.5**
- 41) Rosanò L, Cianfrocca R, Spinella F., Di Castro V, Natali PG, Bagnato A. *Combination therapy of zibotentan with cisplatin and paclitaxel is an effective regimen for epithelial ovarian cancer.* **Can J Physiol Pharmacol.** (2010) 88:676-81. **I.F.1.76**
- 42) Spinella F., Caprara V, Garrafa E, Di Castro V, Rosanò L, Natali PG, Bagnato A. *Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells.* **Can J Physiol Pharmacol.** (2010) 88:782-7. **I.F.1.76**
- 43) Cianfrocca R, Rosanò L, Spinella F., Di Castro V, Natali PG, Bagnato A. *Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase.* **Can J Physiol Pharmacol.** (2010) 88 :796-801. **I.F.1.76**
- 44) Rosano L, Cianfrocca R, Spinella F., Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A. *Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.* **Clin Cancer Res.** (2011) 17:2350-60. **I.F. 7.8**
- 45) Cianfrocca R, Tocci P, Spinella F., Di Castro V, Bagnato A, Rosanò L. *The endothelin A receptor and epidermal growth factor receptor signaling converge on β -catenin to promote ovarian cancer metastasis.* **Life Sci.** (2012) 91:550-6 **I.F. 2.5**
- 46) Garrafa E, Caprara V, Di Castro V, Rosanò L, Bagnato A, Spinella F. *Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells.* **Life Sci.** (2012) **I.F. 2.5**
- 47) Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, Cumashi A, La Sorda R, Spinella F., Bagnato A, Lattanzio R, D'Egidio M, Di Risio A, Stampolidis P, Piantelli M, Natoli C, Ullrich A, Iacobelli S. *LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.* **J Mol Med (Berl).** (2013) 91:83-94. **I.F. 5.3**
- 48) Spinella F., Caprara V, Di Castro V, Rosanò L, Cianfrocca R, Natali PG, Bagnato A. *Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.* **J Mol Med (Berl).** (2013) 91:395-405. **I.F. 5.3**
- 49) Rosanò L, Cianfrocca R, Tocci P, Spinella F., Di Castro V, Spadaro F, Salvati E, Biroccio AM, Natali PG, Bagnato A. *β -arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β -catenin signaling.* **Oncogene.** (2013) Dec 3. **I.F. 6.9**
- 50) Rosanò L, Spinella F., Bagnato A. *Endothelin 1 in cancer: biological implications and therapeutic opportunities.* **Nat Rev Cancer.** (2013) 13:637-51. **I.F. 35**
- 51) Salvati E, Zizza P, Rizzo A, Iachettini S, Cingolani C, D'Angelo C, Porru M, Randazzo A, Pagano B, Novellino E, Pisanu ME, Stoppacciaro A, Spinella F., Bagnato A, Gilson E, Leonetti C, Biroccio A. Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. **Nucleic Acids Res.** (2014) 42:2945-57. **I.F. 8.2**
- 52) Spinella F, Caprara V, Cianfrocca R, Rosanò L, Di Castro V, Garrafa E, Natali PG, Bagnato A. *The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.* **Carcinogenesis.** (2014) 35:840-8. **I.F. 5.6**
- 53) Cianfrocca R, Tocci P, Semprucci E, Spinella F., Di Castro V, Bagnato A, Rosanò L. *β -Arrestin 1 is required for endothelin-1-induced NF- κ B activation in ovarian cancer cells.* **Life Sci.** (2014). doi: 10.1016/j.lfs.2014.01.078. **I.F. 2.6**
- 54) Traini S, Piccolo E, Tinari N, Rossi C, La Sorda R, Spinella F., Bagnato A, Lattanzio R, D'Egidio M, Di Risio A, Tomao F, Grassadonia A, Piantelli M, Natoli C, Iacobelli S. *Inhibition of tumor growth and angiogenesis by*

- SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. **Mol Cancer Ther.** (2014) 13:916-25. **I.F. 5.6**
- 55) Caprara V, Scappa S, Garrafa E, Di Castro V, Rosanò L, Bagnato A, Spinella F. Endothelin-1 regulates hypoxia-inducible factor-1 α and -2 α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells. **Life Sci.** (2014) pii: S0024-3205(14)00287-2. **I.F. 2.5**
 - 56) Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A Endothelin A receptor/ β -arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. **Cancer Res.** (2014);74:7453-64. **I.F.8.6**
 - 57) Bono S, Biricik A, Spizzichino L, Nuccitelli A, Minasi MG, Greco E, Spinella F, Fiorentino F. Validation of a semiconductor next-generation sequencing (NGS)-based protocol for preimplantation genetic diagnosis of reciprocal translocations. **Prenat Diagn.** 35:938-44. 2015 **I.F. 2.5**
 - 58) Fiorentino F, Bono S, Pizzuti F, Mariano M, Polverari A, Duca S, Sessa M, Baldi M, Diano L, Spinella F. The importance of determining the limit of detection of non-invasive prenatal testing methods. **Prenat Diagn.** 2016 36:304-11. **I.F. 2.5**
 - 59) Fiorentino F, Bono S, Pizzuti F, Mariano M, Polverari A, Duca S, Sessa M, Baldi M, Diano L, Spinella F. Response to "The importance of determining the limit of detection of non-invasive prenatal testing methods". **Prenat Diagn.** 2016;36:898-9. **I.F. 2.5**
 - 60) Minasi MG, Colasante A, Riccio T, Ruberti A, Casciani V, Scarselli F, Spinella F, Fiorentino F, Varricchio MT, Greco E. Correlation between aneuploidy, standard morphology evaluation and morphokinetic development in 1730 biopsied blastocysts: a consecutive case series study. **Hum Reprod.** 2016;31:2245-54. **I.F. 5.02**
 - 61) Fiorentino F, Bono S, Pizzuti F, Mariano M, Polverari A, Duca S, Sessa M, Baldi M, Diano L, Spinella F. The importance of determining the limit of detection of non-invasive prenatal testing methods. **Prenat Diagn.** 2016;36:304-11. **I.F. 5.02**
 - 62) Fiorentino F, Bono S, Pizzuti F, Duca S, Polverari A, Faieta M, Baldi M, Diano L, Spinella F. The clinical utility of genome-wide non invasive prenatal screening. **Prenat Diagn.** 2017;37:593-601. **I.F. 5.02**
 - 63) Fiorentino F, Bono S, Pizzuti F, Duca S, Polverari A, Faieta M, Baldi M, Diano L, Spinella F. Author's reply to Grati and Benn. **Prenat Diagn.** 2017;37:1053-1054. **I.F. 5.02**
 - 64) Fiorentino F, Bono S, Pizzuti F, Duca S, Polverari A, Faieta M, Baldi M, Diano L, Spinella F. Author's reply to Grati and Benn. **Prenat Diagn.** 2017;37:1053-1054 **I.F. 5.02**
 - 65) Spinella F, Fiorentino F, Biricik A, Bono S, Ruberti A, Cotroneo E, Baldi M, Cursio E, Minasi MG, Greco E. Extent of chromosomal mosaicism influences the clinical outcome of in vitro fertilization treatments. *Fertil Steril.* 2018;109:77-83 **I.F. 4.5**
 - 66) Minasi MG, Fiorentino F, Ruberti A, Biricik A, Cursio E, Cotroneo E, Varricchio MT, Surdo M, Spinella F, Greco E. Genetic diseases and aneuploidies can be detected with a single blastocyst biopsy: a successful clinical approach. *Hum Reprod.* 2017;32:1770-1777. **I.F. 5.02**
 - 67) Munné S, Spinella F, Grifo J, Zhang J, Beltran MP, Fragouli E, Fiorentino F Clinical outcomes after the transfer of blastocysts characterized as mosaic by high resolution Next Generation Sequencing- further insights. *Eur J Med Genet.* 2019 Aug 21:103741.
 - 68) Allegretti M, Cottone G, Carboni F, Cotroneo E, Casini B, Giordani E, Amoreo CA, Buglioni S, Diodoro M, Pescarmona E, Zazza S, Federici O, Zeuli M, Conti L, Cigliana G, Fiorentino F, Valle M, Giacomini P, Spinella F. Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy. *J Exp Clin Cancer Res.* 2020 Apr 20;39(1):69
 - 69) ESHRE PGT-SR/PGT-A Working Group, Coonen E, Rubio C, Christopikou D, Dimitriadou E, Gontar J, Goossens V, Maurer M, Spinella F, Vermeulen N, De Rycke M. ESHRE PGT Consortium good practice recommendations for the detection of structural and numerical chromosomal aberrations. *Hum Reprod Open.* 2020 May 29;2020(3).
 - 70) La Marca A, Capuzzo M, Sacchi S, Imbrogno MG, Spinella F, Varricchio MT, Minasi MG, Greco P, Fiorentino F, Greco E. Comparison of euploidy rates of blastocysts in women treated with progestins or GnRH antagonist to prevent the luteinizing hormone surge during ovarian stimulation. *Hum Reprod.* 2020 Jun 1;35(6):1325-1331.
 - 71) Dinami R, Porru M, Amoreo CA, Sperduti I, Mottolise M, Buglioni S, Marinelli D, Maugeri-Saccà M, Sacconi A, Blandino G, Leonetti C, Di Rocco G, Verdina A, Spinella F, Fiorentino F, Ciliberto G, Biroccio A, Zizza P. TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. *J Exp Clin Cancer Res.* 2020 Jun 15;39(1):111

- 72) La Marca A, Capuzzo M, Imbrogno MG, Donno V, Spedicato GA, Sacchi S, Minasi MG, Spinella F, Greco P, Fiorentino F, Greco E. The complex relationship between female age and embryo euploidy. *Minerva Ginecol.* 2020 Dec 11. doi: 10.23736/S0026-4784.20.04740-1.
- 73) Ganci F, Allegretti M, Manciocco V, Fiorentino F, Sanguineti G, Giacomini P, Pellini R, Spinella F, Blandino G. Two distinct TP53 mutations in HNSCC primary tumor: Only one circulates in the blood. *Oral Oncol.* 2020 Nov 21:105096.
- 74) Sacconi A, Donzelli S, Pulito C, Ferrero S, Spinella F, Morrone A, Rigoni M, Pimpinelli F, Ensoli F, Sanguineti G, Pellini R, Agrawal N, Izumchenko E, Ciliberto G, Gianni A, Muti P, Strano S, Blandino G. Tmprss2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. *J Exp Clin Cancer Res.* 2020 Sep 23;39(1):200.
- 75) Oliveri S, Marton G, Vergani L, Cutica I, Gorini A, Spinella F, Pravettoni G. Genetic Testing Consumers in Italy: A Preliminary Investigation of the Socio-Demographic Profile, Health-Related Habits, and Decision Purposes. *Front Public Health.* 2020 Oct 8;8:511. doi: 10.3389/fpubh.2020.00511
- 76) Viotti M, Victor AR, Barnes FL, Zouves CG, Besser AG, Grifo JA, Cheng EH, Lee MS, Horcajadas JA, Corti L, Fiorentino F, Spinella F, Minasi MG, Greco E, Munné S. Using outcome data from one thousand mosaic embryo transfers to formulate an embryo ranking system for clinical use. *Fertil Steril.* 2021 Mar 5:S0015-0282(20)32716-3. doi: 10.1016/j.fertnstert.2020.11.041
- 77) Biricik A, Cotroneo E, Minasi MG, Greco PF, Bono S, Surdo M, Lecciso F, Sessa M, Fiorentino F, Spinella F, Greco E. Cross-Validation of Next-Generation Sequencing Technologies for Diagnosis of Chromosomal Mosaicism and Segmental Aneuploidies in Preimplantation Embryos Model. *Life (Basel).* 2021 Apr 12;11(4):340. doi: 10.3390/life11040340. PMID: 33921258; PMCID: PMC8069536
- 78) Viotti M, McCoy RC, Griffin DK, Spinella F, Greco E, Madjunkov M, Madjunkova S, Librach CL, Victor AR, Barnes FL, Zouves CG. Let the data do the talking: the need to consider mosaicism during embryo selection. *Fertil Steril.* 2021 Nov;116(5):1212-1219.
- 79) Somigliana E, Costantini MP, Filippi F, Terenziani M, Riccaboni A, Nicotra V, Rago R, Paffoni A, Mencaglia L, Magnolfi S, Zuccarello D, Rienzi L, Spinella F, Capalbo A, Scaravelli G, Testa S; MUTAGENS Special Interest Group on parenting and fertility. Fertility counseling in women with hereditary cancer syndromes. *Crit Rev Oncol Hematol.* 2022 Mar;171:103604
- 80) Greco E, Yakovlev P, Kornilov N, Vyatkina S, Bogdanova D, Ermakova M, Tarasova Y, Tikhonov A, Pendina A, Biricik A, Sessa MT, Listorti I, Ronsini C, Greco PF, Victor A, Barnes F, Zouves C, Spinella F, Viotti M. Two clinical case reports of embryonic mosaicism identified with PGT-A persisting during pregnancy as true fetal mosaicism. *Hum Reprod.* 2023 Feb 1;38(2):315-323.
- 81) ESHRE PGT Consortium data collection XXI: PGT analyses in 2018. Spinella F, Bronet F, Carvalho F, Coonen E, De Rycke M, Rubio C, Goossens V, Van Montfoort A. *Hum Reprod Open.* 2023 Apr 19;2023(2):hoad010. doi: 10.1093/hropen/hoad010. eCollection 2023. PMID: 37091225

Rome 4, May 2023

Francesca Spinella

